Novartis to acquire US-based cancer drugmaker Endocyte for $2.1b

Novartis to acquire US-based cancer drugmaker Endocyte for $2.1b

Photo: Reuters

19 October, 2018

Endocyte Novartis

Printed by Unregistered user on Thu, 25 Dec 2025 00:31:42 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

Read more from World

Viewpoint: The structural case for APAC private credit in 2026

Blackstone to acquire Australia’s iconic Hamilton Island for $1b